New York, USA – Creative Biolabs, known as an expert in the viral vaccine development field, releases brand new Coronaviridae Family Vaccine Development Services to meet the rapidly increasing needs of global academic and scientific clients.
As a family of single-stranded, enveloped, positive RNA viruses, Coronaviridae viruses are mostly referred to as the culprit of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In fact, the Coronaviridae family also includes canine coronavirus, and bovine coronavirus. Equipped with an advanced mRNA vaccine platform and years of hand-on experience, Creative Biolabs can offer clients professional solutions to the design, production, and evaluation of Coronaviridae Family Vaccine. The exclusive platform enables non-infectious and non-integrating symptoms, a regulable in vivo half-life, capacity for low-cost and rapid scalable manufacture.
Canine Coronavirus Vaccines
Canine coronavirus (CCoV) results in contagious enteritis of variable severity in the dog population. Creative Biolabs develops two types of vaccines against canine coronavirus, inactivated coronavirus, or combination vaccines with others that can protect dogs.
Bovine Coronavirus Vaccines
Bovine coronavirus (BoCV) is a virus with a worldwide distribution, which can lead to diarrhea in young calves and winter dysentery in dairy cows, or occasionally induce respiratory disease in calves 2-16 weeks of age. Scientists at Creative Biolabs are skillful in developing vaccines for a productive immune system for cattle with more BCoV antibodies.
Creative Biolabs not only provides inactivated SARS-CoV-based vaccines, S protein-based vaccines, and vaccines based on fragments containing neutralizing epitopes, but also can help clients with the innovative and safe SARS vaccines that elicit potent neutralizing antibody responses and induce protection.
Middle East Respiratory Syndrome (MERS) Vaccine
At Creative Biolabs, live attenuated MERS-CoV vaccines and DNA vaccines are provided for the research of MERS, which can induce potent neutralizing antibodies in mice and neutralizing antibodies and T-cell responses in non-human primates.
“We have engaged in the development of Vaccines for Virus from Coronaviridae Family for over 10 years and have accumulated sufficient experience how to customize a high-quality solution within a fast turnaround time. We can perfectly adjust protocols in terms of client needs and we are always glad to share our expertise. That’s how we gained customers’ trust,” said the manager at Creative Biolabs.
More information on vaccine services can be found at https://www.creative-biolabs.com/vaccine.
About Creative Biolabs
Creative Biolabs, headquartered in New York, is a leading custom service provider in the field of vaccine development, preclinical assessment and GMP manufacturing. The technical and regulatory experts can provide vaccine developers with a full range of products and vaccine related services. Traditional and the most updated genetic engineering technologies are combined to efficiently produce highly immunogenic and safe vaccines to address emergency unmet medical needs. The service portfolio includes a full range of vaccine design for client’s specific requirements that covers vaccine target validation, vaccines targeting bacterial, viral, fungal, parasites, cancer markers and more. Formulation optimization services are also available for maximum potency, including improving delivery systems, a great variety of adjuvant products and services like PRR Ligands scanning and adjuvants synthesis.